Recent Updates
Recently added Catalysts

WIN378

Phase 2

Asthma | Small Molecules | Respiratory |Windward Bio Group AG|Trials Updated: Oct 23, 2026

WIN378 development status

Highest phase Phase 2
Registered trials 2 across 1 sponsor since Aug 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials2
Total Enrollment705

FDA Designations

No designations recorded

WIN378 clinical trials

WIN378 · 2 trials · 2 indications

Phase 2 2
NCT07646587A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)COPD (Chronic Obstructive Pulmonary Disease)
RECRUITING105 Analytics
NCT07120503Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe AsthmaAsthma
RECRUITING600 Analytics
PHASE2RECRUITING
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
COPD (Chronic Obstructive Pulmonary Disease)Unlock trial analytics
PHASE2RECRUITING
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
AsthmaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with Adverse Events (AEs)
Week 0 - Week 36
Number of participants with Serious Adverse Events (SAEs)
Week 0 - Week 36
Change from baseline in systolic blood pressure (mmHg)
Week 0 - Week 36
Change from baseline in diastolic blood pressure (mmHg)
Week 0 - Week 36
Change from baseline in pulse rate (beats/minute)
Week 0 - Week 36
Change from baseline in respiratory rate (breaths/minute)
Week 0 - Week 36
Change from baseline in oxygen saturation (%)
Week 0 - Week 36
Change from baseline in body weight (kg)
Week 0 - Week 36
Change from baseline in body mass index (kg/m^2)
Week 0 - Week 36
Change from baseline in body temperature (°C)
Week 0- Week 36
Change from baseline in clinical chemistry laboratory assessments
Week 0 - Week 36

Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.

Change from baseline in haematology laboratory parameters
Week 0 - Week 36

Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count

Change from baseline in coagulation laboratory parameters
Week 0 - Week 36

Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen

Change from baseline in urinalysis parameters
Week 0 - Week 36

Urinalysis assessments will include protein, pH, blood, glucose and leucocytes

Change from baseline in electrocardiogram QT interval
Week 0 - Week 36

Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)

WIN378 Serum concentration (PK)
Week 0 to week 36
PART A: Number of participants with treatment-emergent adverse events (TEAEs) during the study
Week 0 - Week 60
PART A: Number of participants with treatment-emergent serious adverse events (TESAEs) during the study
Week 0 - Week 60
PART A: Number of participants with abnormal vital signs during the study
Week 0 - Week 60
PART A: Number of participants with abnormal laboratory assessments during the study
Week 0 - Week 60
PART A: Number of participants with Clinically significant abnormal ECG results during the study
Week 0 - Week 60
PART A: WIN 378 Pharmacokinetics: concentration at trough [Ctrough]
Week 0 - Week 60
PART A: WIN 378 Pharmacokinetics: area under the concentration time curve [AUC]
Week 0 - Week 60
PART A: WIN 378 Pharmacokinetics: maximum observed concentration [Cmax])
Week 0 - Week 60
PART A: Number of participants with positive anti-drug antibodies (ADA) during the study
Week 0 - Week 60
PART B: Annualized Asthma Exacerbation Rate (AAER)
24 Weeks after last dose

Secondary Endpoints

Change from baseline in Blood Eosinophil Count
Week 0 to Week 24
Change in Fractional Exhaled Nitric Oxide (FeNO)
Week 0 to Week 24
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Week 0 to Week 24
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
WIN378 Dose 1EXPERIMENTALWIN378 SC injections will be administered
WIN378 Dose 2EXPERIMENTALWIN378 SC injections will be administered
PlaceboEXPERIMENTALPlacebo SC injections will be administered
WIN378EXPERIMENTALWIN378 SC injections

Interventions

NameTypeDescription
WIN378DRUGWIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
PlaceboDRUGPlacebo matching WIN378
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites32

Inclusion Criteria: * Adults aged 40 to 80 years * Post-BD spirometry at screening FEV1/FVC \< 0.70 and FEV1 30-80% predicted * On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months * Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months * Elevated eosinophil c...

Countries:United StatesArgentinaAustraliaBulgariaFranceGermanySpainSweden
Unlock Eligibility Criteria